News Archive

November 2023
Memo Therapeutics

Memo Therapeutics AG Appoints Erik van den Berg as Chief Executive Officer (CEO)
November 2023
Araris Biotech

Araris Biotech AG Announces Research Collaboration with Taiho Pharmaceutical to Develop Next-Generation ADCs Using Araris’ Proprietary Linker-Conjugation Technology
November 2023
Memo Therapeutics

Memo Therapeutics AG Raises CHF 25 Million Series C Financing to Complete Phase II Clinical Development of AntiBKV for BKV Infection in Renal Transplant Patients
October 2023
Mediar Therapeutics

Mediar Therapeutics Announces Clinical Candidates for Lead Fibrosis Programs, Strategic Collaborations and Key Leadership Addition
October 2023
AM Pharma

AM-Pharma Announces Positive Clinical Data from Phase 1B Study Evaluating Ilofotase Alfa in Hypophosphatasia Patients
October 2023
Araris Biotech

Araris Biotech AG Appoints Co-Founder and Chairman Dr. Dragan Grabulovski as Chief Executive Officer (CEO)
October 2023
Ariceum Therapeutics

Ariceum Therapeutics Targeted Radiopharmaceutical 177Lu-Satoreotide Exhibits Promising Clinical Response and Good Tolerability Profile in Patients with Advanced Neuroendocrine Tumours
September 2023
AM Pharma

AM-Pharma announced the Appointment of Juliane Bernholz as Chief Executive Officer and an Update of the Clinical Development Strategy. Ilofotase Alfa will be developed in Cardiac Surgery-associated Renal Damage and Hypophosphatasia.

We are looking forward continuing the journey to benefit patients.

September 2023
Acrivon Therapeutics

Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon’s AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies
September 2023
Ariceum Therapeutics

Ariceum Therapeutics Doses First Patient with its First-in-class Targeted Radiopharmaceutical Drug Satoreotide in its Phase IB Study in Small Cell Lung Cancer
August 2023
Alentis Therapeutics

Alentis Therapeutics receives FDA Fast Track Designation for ALE.C04 for the Treatment of Claudin-1 Positive HNSCC
August 2023
Hummingbird Bioscience

Hummingbird Bioscience Initiates HMBD-001 Phase IB Trials in Australia and Partners with Omico to Accelerate Clinical Development 
July 2023
Alentis Therapeutics

Alentis Therapeutics Announces First Patient Dosed in Phase 1b “FEGATO-01” Clinical Trial of ALE.F02 for the Treatment of Liver Fibrosis
June 2023
Alentis Therapeutics

Alentis Therapeutics Appoints Luca Santarelli as Chairperson
June 2023
MinervaX

MinervaX Announces Completion of Enrolment in Phase 1 Clinical Vaccine Trial as it Addresses the Global Burden of Group B Streptococcus in Older Adults
June 2023
Alentis Therapeutics

Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
June 2023
Ariceum Therapeutics

Ariceum Snaps up Fellow European Biotech Theragnostics to Bolster Radiopharma Efforts
June 2023
Ariceum Therapeutics

Ariceum Therapeutics Expands Pipeline with Acquisition of Theragnostics Ltd
June 2023
Pureos Bioventures

Pureos Partners further Strengthens its Team and Announces Promotions
May 2023
Engimmune Therapeutics

Engimmune Therapeutics Announces the Appointment of Dr Annalisa D’Andrea to its Board of Directors
May 2023
Hummingbird Bioscience

Hummingbird Bioscience and Merck Enter Collaboration to Evaluate HMBD-001 In Squamous Non-Small Cell Lung Carcinoma
May 2023
Ariceum Therapeutics

UCB and Ariceum Therapeutics sign a Strategic Research Collaboration to Discover New Modalities for the Treatment of Immune-related Diseases and Cancer
May 2023
Hummingbird Bioscience

Hummingbird Bioscience to Present Preclinical Proof of Concept for Potentially First-In-Class Antibody Targeting Autoimmune Diseases
May 2023
Araris Biotech

Araris Biotech AG Supported with CHF 2.5M Swiss Accelerator Grant from Innosuisse to Develop Antibody-Drug Conjugate Candidates
April 2023
Alentis Therapeutics

Alentis Therapeutics Reports Positive Topline Results From Phase 1 Multiple-ascending Dose Cohorts Study
April 2023
Engimmune Therapeutics

Engimmune Therapeutics Appoints Dr. Lars Nieba as Chief Executive Officer
April 2023
ImCheck Therapeutics

ImCheck Achieves the Primary Objectives of Phase I of the EVICTION-2 Trial of ICT01 in Combination with Low Dose IL-2, Data Presented at AACR 2023
April 2023
Ariceum Therapeutics

Ariceum Therapeutics Announces Extension of Series A Financing to EUR 47.75M to Advance its Next Generation Radiopharmaceutical Clinical Pipeline
April 2023
Araris Biotech

Araris Biotech AG Acquires ARS Pharmaceutical’s Nectin-4 Antibody
April 2023
MinervaX

MinervaX Commences First Phase 1 Clinical Study of Novel GBS Vaccine in Older Adults
April 2023
Alentis Therapeutics

Alentis Therapeutics Closes $105 Million Series C Funding to Advance Transformational Medicines for Claudin-1
April 2023
Araris Biotech

Araris Biotech AG Announces Strategic Investment with Samsung Ventures
April 2023
Vico Therapeutics

Vico Therapeutics Announces First Patient Dosed in Phase 1/2a Clinical Trial of VO659 in Huntington’s Disease and Spinocerebellar Ataxia Types 1 and 3 
March 2023
ImCheck Therapeutics

ImCheck Appoints Thomas Civik as Independent Chairman of the Board
March 2023
Araris Biotech

Araris Biotech AG to Present Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2023
March 2023
ImCheck Therapeutics

ImCheck To Present Data From the EVICTION-2 Study of ICT01 in Combination With IL-2 In Patients with Advanced Solid Tumors at AACR
March 2023
Mediar Therapeutics

Mediar Therapeutics Announces $105 Million Financing to Advance Portfolio of First-in-Class Fibrosis Therapies
March 2023
Hummingbird Bioscience

Hummingbird Bioscience Exercises Its Option to License the Clinical Trial Results from Cancer Research UK to Support Further Development of HMBD-001
March 2023
Pureos Bioventures

Pureos Partners Welcomes Prof. Dr. Sai Reddy to its Team as Venture Partner
February 2023
Lava Therapeutics

Lava Therapeutics Announces Initial Data from the Ongoing Phase 1/2A Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium
February 2023
Ariceum Therapeutics

Ariceum Therapeutics Appoints Radioligand Expert, Germo Gericke, M.D., as Chief Medical Officer
January 2023
Pureos Bioventures

Pureos Partners Welcomes Dr. Ulf Grawunder to its Team as Venture Partner
January 2023
Alentis Therapeutics

Positive Results from Single Ascending Dose Phase 1 Study of ALE.F02 Targeting Claudin-1
January 2023
MinervaX

MinervaX Appoints Lidia Oostvogels as Chief Medical Officer and Provides Clinical and Regulatory Update on its Novel GBS Vaccine
January 2023
Alentis Therapeutics

Alentis Therapeutics Appoints Dr. Luigi Manenti as Chief Medical Officer
January 2023
Hummingbird Bioscience

Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program
December 2022
MinervaX

MinervaX Announces 72M EUR Financing to Advance Development of Novel Vaccine against Group B Streptococcus
December 2022
Hummingbird Bioscience

Caris Life Sciences and Hummingbird Bioscience Enter Into Collaboration to Advance Clinical Development of Anti-HER3 Therapy
November 2022
Acrivon Therapeutics

Acrivon Therapeutics Announces Pricing of Initial Public Offering
November 2022
ImCheck Therapeutics

ImCheck Presents Initial Patient Data from the EVICTION-2 Clinical Trial at SITC Annual Meeting
November 2022
Alentis Therapeutics

Alentis Therapeutics Announces Presentations at AASLD The Liver Meeting® 2022
November 2022
Alentis Therapeutics

Alentis Therapeutics, Inserm and University of Strasbourg Article Published in The Journal of Hepatology Highlights Potential of Claudin-1 as a Novel Target for the Treatment of Hepatocellular Carcinoma
November 2022
Pureos Bioventures

Pureos Partners receives FINMA License as Portfolio Manager
October 2022
Ariceum Therapeutics

Ariceum Therapeutics and AmbioPharm Enter Strategic Manufacturing and Supply Partnership
October 2022
Ariceum Therapeutics

Ariceum Therapeutics Announces Planned Retirement of CMO
October 2022
AM-Pharma

AM-Pharma Provides Business Update and Outcome of Pre-planned Interim Futility Analysis of Phase 3 REVIVAL Study
October 2022
Alentis Therapeutics

Swiss Innovation Agency to co-fund Research Collaboration to Accelerate Discovery of Biomarkers for Fibrosis
October 2022
Araris Biotech

Araris Biotech Closes $24 Million Financing Round
October 2022
Vico Therapeutics

Vico Therapeutics Appoints Scott Schobel, MD as Chief Medical Officer
September 2022
Pureos Bioventures

Pureos Partners Welcomes Dr. Veronica Gambillara Fonck as New Partner to its Investment Team
September 2022
Lava Therapeutics

Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors
September 2022
Tridek-One

Tridek-One Closes a €16 Million Financing Round To Develop First-in-class Immune Checkpoint Agonists
September 2022
Hummingbird Bioscience

Hummingbird Bioscience Announces Trial in Progress Poster Presentation at the European Society for Medical Oncology Congress 2022
September 2022
ImCheck Therapeutics

ImCheck Presents Positive Safety and Efficacy Data from the Completed Phase 1 Dose Escalation Cohort of ICT01 plus Pembrolizumab in the EVICTION Trial at ESMO Congress 2022
August 2022
Vico Therapeutics

Vico Therapeutics Appoints Micah Mackison as Chief Executive Officer
July 2022
Ariceum Therapeutics

Ariceum Therapeutics Appoints Chief Business Officer
June 2022
Acrivon Therapeutics

Akoya Biosciences to Partner with Acrivon Therapeutics for the Clinical Development of Acrivon’s Proprietary OncoSignature® Test into a Companion Diagnostic
June 2022
Acrivon Therapeutics

Acrivon Therapeutics Receives FDA Clearance for Innovative Phase 2 Trial to Treat Ovarian, Endometrial and Urothelial Cancer Patients Based on Predicted Sensitivity to ACR-368
June 2022
ImCheck Therapeutics

ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of First-in-human Gamma-delta T Cell Activating Antibody and Accelerate Development of Disruptive Immunotherapeutic Pipeline
June 2022
Ariceum Therapeutics

Ariceum Therapeutics Launches with EUR 25M Series A to Advance Lead Asset, Satoreotide, for the Treatment of Low- and High-Grade Neuroendocrine Cancers
May 2022
Alentis Therapeutics

Alentis Therapeutics Appoints Dr. Andrea Pellacani as Chief Medical Officer
May 2022
Engimmune Therapeutics

Engimmune Therapeutics Raises CHF 15.5 Million in Seed Financing to Develop Novel T-Cell Receptor Therapeutics
April 2022
AM-Pharma

400 Patients Have Been Enrolled an AM-Pharma’s Pivotal Phase 3 Study of Ilofotase Alfa for the Treatment of Sepsis-Associated Acute Kidney Injury
April 2022
Acrivon Therapeutics

Acrivon Therapeutics Announces the Appointments of Rasmus Holm-Jorgensen as Chief Financial Officer and Other Senior Executives
April 2022
Araris Biotech

Araris Biotech AG Presents Preclinical Data Highlighting Anti-CD79b ADC Program and Late-Breaking Data on Nectin-4 ADC at the American Association for Cancer Research (AACR) 2022 Annual Meeting
April 2022
ImCheck Therapeutics

ImCheck Provides Updated ICT01 and Pembrolizumab Combination Data from the Phase I/IIa EVICTION Trial at AACR Annual Meeting 2022
March 2022
Lava Therapeutics

LAVA Therapeutics Presents Initial LAVA-051 Clinical Data at the ESMO Targeted Anticancer Therapies Congress 2022
February 2022
Hummingbird Bioscience

Hummingbird Bioscience Publishes Preclinical Data Demonstrating Therapeutic Potential of HMBD-002 in VISTA-expressing Cancers
February 2022
ImCheck Therapeutics

ImCheck Announces First Patients Dosed in Phase II of EVICTION Trial for ICT01
February 2022
Lava Therapeutics

LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-1207 for Metastatic Castration-Resistant Prostate Cancer
February 2022
ImCheck Therapeutics

For the third year in a row, ImCheck has been awarded by the French Tech as one of the top 120 French start-ups/scale-ups and among 7 French biotech developing innovative therapies
January 2022
ImCheck Therapeutics

ImCheck to Present at 40th Annual J.P. Morgan Healthcare Conference
January 2022
Alentis Therapeutics

Alentis Therapeutics Starts First-in-Human Clinical Trial for the Treatment of Liver and Kidney Fibrosis
December 2021
Acrivon Therapeutics

Acrivon Therapeutics Announces its Scientific Advisory Board with Renowned Oncology Thought Leaders
December 2021
Hummingbird Bioscience

Hummingbird Bioscience Announces First Patient Dosed in Phase 1 Clinical Trial of HMBD-001 in Advanced HER3-Expressing Solid Malignancies
November 2021
Hummingbird Bioscience

Hummingbird Bioscience Appoints Jan Møller Mikkelsen as Chairman of the Board
November 2021
Lava Therapeutics

LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results
November 2021
ImCheck Therapeutics

ImCheck Provides Promising Updated Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at SITC Meeting 2021
November 2021
Pureos Bioventures

Pureos Bioventures Invests in Acrivon Therapeutics
November 2021
Araris Biotech

Araris is Expanding its Scientific Advisory Board with Dr. Jeff Sharman and Dr. Clive Stanway
November 2021
Hummingbird Bioscience

Hummingbird Bioscience Announces Trials in Progress Poster Presentation at the Society for Immunotherapy of Cancer 2021 36th Annual Meeting
November 2021
Pureos Bioventures

Pureos Bioventures Welcomes Dr. Lars Nieba to its Team as Venture Partner
November 2021
Alentis Therapeutics

Alentis Therapeutics Announces Appointments of Luca Santarelli to the Board of Directors and Rafaele Tordjman as Chairperson
October 2021
Hummingbird Bioscience

Hummingbird Bioscience to Collaborate with Merck on Clinical Trial of Anti-VISTA Antibody HMBD-002 in Combination with KEYTRUDA® (Pembrolizumab) for Treatment of Cancer
October 2021
ImCheck Therapeutics

ImCheck Publishes Comprehensive Overview of the Development Results of Its First-in-class Cancer Immunotherapeutic Targeting BTN3A to Activate Vγ9Vδ2 T Cells in Science Translational Medicine
October 2021
Lava Therapeutics

LAVA Therapeutics Receives FDA Orphan Drug Designation for LAVA-051 for the Treatment of Chronic Lymphocytic Leukemia
October 2021
Hummingbird Bioscience

Hummingbird Bioscience to Present Pre-Clinical Data on Novel Biomarkers for HER3-Driven Cancers
September 2021
Hummingbird Bioscience

Hummingbird Bioscience Opens New Office and Research Facilities
September 2021
Pureos Bioventures

Pureos Bioventures Expands the Team by the Appointment of Venture Partners
September 2021
ImCheck Therapeutics

ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021
September 2021
Araris Biotech

Araris Biotech Shortlisted in Top 5 of World ADC Awards 2021 in Category “Best ADC Platform Technology“
September 2021
Hummingbird Bioscience

Hummingbird Bioscience Announces US FDA Clearance of IND for First-in-Human Phase 1 Trial of HMBD-002 in Patients with Advanced Solid Tumors
September 2021
ImCheck Therapeutics

ImCheck to Present Early Patient Response Data from the EVICTION Trial at the ESMO Congress 2021
September 2021
Araris Biotech

Araris Biotech Ranks TOP11 at Swiss Startup Award 2021
September 2021
AM-Pharma

AM-Pharma and Kyowa Kirin Sign Exclusive License Agreement for Commercialization of Ilofotase Alfa in Japan
August 2021
Lava Therapeutics

LAVA Therapeutics Provides Business Update and Reports Second Quarter Results
August 2021
Eyevensys

Eyevensys Raises $12M in a Series B Plus Funding Round
July 2021
Alentis Therapeutics

Alentis Therapeutics Raises USD 67 Million in Series B Financing
July 2021
Lava Therapeutics

LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-051 for Multiple Hematological Malignancies
July 2021
ImCheck Therapeutics

ImCheck Publishes Seminal Paper in Cell Reports Elucidating How Butyrophilins Activate Vγ9Vδ2 T cell Function Against Tumor Cells
July 2021
AM-Pharma

AM-Pharma Appoints Mark Altmeyer as Chairman of its Supervisory Board
July 2021
AM-Pharma

AM-Pharma Enrolls First Patient in Japan for Ongoing Phase III SA-AKI Pivotal REVIVAL Trial
June 2021
Corlieve Therapeutics

uniQure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE)
May 2021
Hummingbird Bioscience

Hummingbird Bioscience Raises US$125 Million in Series C Financing
April 2021
ImCheck Therapeutics

ImCheck Announces Initiation of U.S. Enrollment in Phase I/IIa EVICTION Trial for ICT01
April 2021
Pureos Bioventures

Pureos Bioventures Expands Fund Size to USD 205 Million
More News News Archive